$-0.22 EPS Expected for Histogenics Corporation (HSGX)

February 15, 2018 - By Henry Gaston

 $ 0.22 EPS Expected for Histogenics Corporation (HSGX)

Analysts expect Histogenics Corporation (NASDAQ:HSGX) to report $-0.22 EPS on March, 15.They anticipate $1.38 EPS change or 86.25 % from last quarter’s $-1.6 EPS. After having $-0.23 EPS previously, Histogenics Corporation’s analysts see -4.35 % EPS growth. The stock decreased 1.17% or $0.03 during the last trading session, reaching $2.54. About 39,093 shares traded. Histogenics Corporation (NASDAQ:HSGX) has declined 7.61% since February 15, 2017 and is downtrending. It has underperformed by 24.31% the S&P500.

Histogenics Corporation (NASDAQ:HSGX) Ratings Coverage

Among 6 analysts covering Histogenics Corp (NASDAQ:HSGX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Histogenics Corp had 16 analyst reports since August 27, 2015 according to SRatingsIntel. BTIG Research upgraded Histogenics Corporation (NASDAQ:HSGX) on Friday, August 12 to “Buy” rating. On Monday, December 19 the stock rating was initiated by H.C. Wainwright with “Buy”. Canaccord Genuity maintained it with “Buy” rating and $4.0 target in Monday, October 16 report. The rating was downgraded by BTIG Research on Friday, November 13 to “Neutral”. The stock of Histogenics Corporation (NASDAQ:HSGX) has “Buy” rating given on Thursday, December 21 by Canaccord Genuity. William Blair downgraded the shares of HSGX in report on Wednesday, September 7 to “Market Perform” rating. Zacks downgraded Histogenics Corporation (NASDAQ:HSGX) on Thursday, August 27 to “Hold” rating. The stock of Histogenics Corporation (NASDAQ:HSGX) has “Buy” rating given on Monday, September 19 by Needham. Needham maintained the stock with “Buy” rating in Friday, November 13 report. The stock of Histogenics Corporation (NASDAQ:HSGX) earned “Buy” rating by H.C. Wainwright on Wednesday, December 27.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $62.41 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

More notable recent Histogenics Corporation (NASDAQ:HSGX) news were published by: Globenewswire.com which released: “Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as …” on June 05, 2017, also Globenewswire.com with their article: “Histogenics Corporation Announces Second Quarter 2017 Financial and Operating …” published on August 10, 2017, Globenewswire.com published: “Histogenics Announces Agreement With the Japan Pharmaceuticals and Medical …” on May 08, 2017. More interesting news about Histogenics Corporation (NASDAQ:HSGX) were released by: Globenewswire.com and their article: “Histogenics Corporation Announces Closing of Underwritten Registered Direct …” published on January 25, 2018 as well as Gurufocus.com‘s news article titled: “S Squared Technology, LLC Buys Rapid7 Inc, Histogenics Corp, Adtran Inc, Sells …” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.